ScreenerHero

IVVD Invivyd, Inc.

NAS · US · Healthcare · Biotechnology · invivyd.com
0.7286USD-9.65%Mkt Cap: 214.76M $P/E: —

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. T…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap214.76M USD
Enterprise Value86.00M USD
Revenue (TTM)58.37M USD
Gross Profit49.68M USD
Net Income (TTM)-52.49M USD
Revenue/Share0.22 USD
Last Price0.7286 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees122
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.47
PEG—
EV/EBITDA-0.77
EV/Revenue1.47
P/S4.07
P/B1.31
EPS (TTM)-0.32
EPS (Forward)-0.55
52W Range
0.52778% of range3.070
52W High3.070 USD
52W Low0.5277 USD
Profitability
Gross Margin92.99%
Oper. Margin-320.76%
EBITDA Margin-191.70%
Profit Margin-98.25%
ROE-21.73%
ROA-18.96%
Growth
Revenue Growth21.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-58.13M USD
CapEx (TTM)155.00K USD
FCF Margin-119.85%
FCF Yield-32.57%
Net Debt-151.69M USD
Net Debt/EBITDA1.36
Balance Sheet
Debt/Equity0.01
Current Ratio5.87
Quick Ratio5.54
Book Value/Sh0.61 USD
Cash/Share0.54 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+1272.5%
Target Range10.00 USD – 10.00 USD
# Analysts3
Ownership
Shares Out.294.76M
Float207.83M
Insiders7.16%
Institutions86.89%
Short Interest
Short Ratio7.1d
Short % Float11.45%
Short % Out.10.37%
Shares Short30.56M
Short (prev mo.)30.92M
Technical
SMA 500.8014 (-9.1%)
SMA 2001.342 (-45.7%)
Beta0.95
S&P 52W Chg16.45%
Avg Vol (30d)6.22M
Avg Vol (10d)9.35M
Technical Indicators
RSI (14)41.4
MACD-0.0029
MACD Signal0.0170
MACD Hist.-0.0199
BB Upper1.008 USD
BB Middle0.8550 USD
BB Lower0.7021 USD
BB Width35.77%
ATR (14)0.0878 USD
Vol Ratio (20d)1.42x